Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
Saved in:
| Title: | Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. |
|---|---|
| Authors: | Gardner ER; Clinical Pharmacology Program, SAIC-Frederick, NCI-Frederick, Frederick, MD 21702, USA., Kelly M, Springman E, Lee KJ, Li H, Moore W, Figg WD |
| Source: | Investigational new drugs [Invest New Drugs] 2012 Feb; Vol. 30 (1), pp. 90-7. Date of Electronic Publication: 2010 Sep 07. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
